Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
about
Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxaneAntiangiogenesis cocktails - stirred or shaken?New chemotherapy strategies and biological agents in the treatment of childhood ependymomaInvasion and metastasis in pancreatic cancerThe Concept of Hormesis in Cancer Therapy - Is Less More?The Contribution of Angiogenesis to the Process of MetastasisMetronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung CancerTargeting the tumor vasculature to enhance T cell activityTracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations.Future paradigms for precision oncologyTherapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapyPatient perspectives: Tijuana cancer clinics in the post-NAFTA eraSustained delivery of a HIF-1 antagonist for ocular neovascularization.Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer.Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myelomaTreatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy.Retrospective comparison of three doses of metronomic chlorambucil for tolerability and efficacy in dogs with spontaneous cancer.Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice.Stability of cyclophosphamide in extemporaneous oral suspensions.Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy.FOXL2 suppresses proliferation, invasion and promotes apoptosis of cervical cancer cellsAngiogenesis inhibitors in the treatment of prostate cancer.Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics.Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy.Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristineA comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancerCombination therapy in combating cancer.A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast CancerAnti-proliferative and angio-suppressive effect of Stoechospermum marginatum (C. Agardh) Kutzing extract using various experimental modelsA role for survivin in chemoresistance of endothelial cells mediated by VEGFLessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.Targeting angiogenesis with integrative cancer therapies.Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter studyRecent developments in antiangiogenic therapy.VEGF blocking therapy in the treatment of cancer.The merits of vascular targeting for gynecologic malignancies.
P2860
Q24314623-225FE07E-0BB5-4801-B53D-001957A44B99Q24548357-50BD2A9F-A4C2-462C-BE04-F935BBDC3817Q24658324-48E71AA5-AEE8-4F0F-98DB-9B830B09AD6CQ24800065-56ED9856-0DE8-4574-BE85-972D8F062446Q26800519-04245519-11F4-46D2-92C6-9BCCB3CB4093Q26801841-54194AC9-659E-4C93-9F00-607A817C6346Q27015786-3A3C7F5D-AAAD-4B7A-9392-FBA70EFC676EQ27026329-3F85D55D-68B4-4C5A-92CC-A07B27D43CB3Q27335464-31FA07B2-EAFA-4399-9653-DA2EB58C6C38Q28078745-880C332D-CD8C-409A-B6C3-9070CDFFD498Q28253120-2623E207-9C72-4379-A2FA-1DDD04AF6803Q28306156-CB852B61-2AE9-4B0F-90CE-B72C1A984565Q30560557-3F140468-CA41-4A36-BD5B-AA8F37EDE548Q30846827-0F179596-6544-48B7-86B5-F09E4FD006EEQ33403308-94552BAA-3754-45BE-9009-5879A4FDB987Q33408052-9B42F4FC-7CA5-43BE-B1DF-0EEA77475684Q33411816-FA48B4D3-36F6-47A5-B8FF-A2D75CDD1B8DQ33431916-1BAF9451-E8D1-4FC2-BA8C-5946C5104595Q33485606-34DCC988-E2B0-4970-83EA-47808CCB87EDQ33526743-0A925C14-CA2E-4520-8FC5-6EFD3BD09EC9Q33557868-8D31F30E-765E-4BE1-8616-1AD34CAC0AB5Q33582969-35881AAD-D30B-4A94-922B-FFABDBF4FB87Q33611121-E7916DAB-C787-4DFE-83F0-012E2B17D9B0Q33780689-E83A6AA9-8FCA-44E6-B6BA-5AC53246E8DBQ33818307-7D31A75D-A141-48AD-857F-60946D57710EQ33829569-A45718AD-7D8D-43D5-97BE-6231863DD1E4Q33866374-EA36A862-9690-45EB-9D6F-09C5D9271E7FQ33872982-09E6EB17-8F9B-417B-ACD4-C4A4A481E7C2Q33875597-5BAF0E84-9FD4-4073-BF22-41CEFFB82E36Q33914234-B0660BE2-003C-49F7-B3AF-8C75318B2280Q33916210-EE1B1BCF-CBA7-4793-86A3-A1635BAB756DQ34006393-C4A06F1B-9234-466A-B44C-CA2570F3AD81Q34047896-E16E5047-B6FA-4819-990E-50ADBD7B7833Q34173001-583AC25F-31F9-4C30-853C-8CF66723715AQ34403657-B2956931-BAC5-4E05-B825-FDEEA5AD79FBQ34495463-70BDD135-C923-4D46-BE64-C4DA34F9FBD5Q34993605-43A842DF-6C92-458E-9099-DCCA7D8AB178Q35040867-D47B926F-E4B9-4045-86CF-CF07674A49DAQ35093616-24611CAF-5E5D-4157-8680-47D5DD927715Q35116734-6A53C332-B726-40AA-A92A-D7AE4361D43A
P2860
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Less is more, regularly: metro ...... get tumor angiogenesis in mice
@ast
Less is more, regularly: metro ...... get tumor angiogenesis in mice
@en
Less is more, regularly: metro ...... get tumor angiogenesis in mice
@nl
type
label
Less is more, regularly: metro ...... get tumor angiogenesis in mice
@ast
Less is more, regularly: metro ...... get tumor angiogenesis in mice
@en
Less is more, regularly: metro ...... get tumor angiogenesis in mice
@nl
prefLabel
Less is more, regularly: metro ...... get tumor angiogenesis in mice
@ast
Less is more, regularly: metro ...... get tumor angiogenesis in mice
@en
Less is more, regularly: metro ...... get tumor angiogenesis in mice
@nl
P2093
P2860
P356
P1476
Less is more, regularly: metro ...... get tumor angiogenesis in mice
@en
P2093
P2860
P304
P356
10.1172/JCI9872
P407
P577
2000-04-01T00:00:00Z